KLRC1 and acute myeloid leukemia: study demonstrated that the humanized anti-NKG2A antibody converts NKG2A+ NK cells into effector NK cells that induce tumor cell death by killing most HLA-E+ NK resistant lymphohematopoietic cells such as dendritic cells, myeloid cells, B and T lymphocytes, and leukemic cells including AML amongst other cell types.